The effect of synbiotic supplementation in the treatment of fatty liver

Phase 3

• Conditions: Condition 1: Fatty Liver. Condition 2: Type 2 diabetes mellitus.; Fatty (change of) liver, not elsewhere classified; Type 2 diabetes mellitus; K76.0

• Registration Number: IRCT20240212060977N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Having fatty liver (grade 2 or 3)
Having diabetes or prediabetes (fasting blood sugar above 100)
Being overweight or obese (BMI greater than 25)
Aged 18 or higher from both male and female genders
Not taking insulin
Not being pregnant or breastfeeding
Not suffering from certain diseases, including metabolic, respiratory, and kidney diseases
Not taking antibiotics or probiotic or synbiotic supplements in the 3 months before the study

Exclusion Criteria

Suffering from certain diseases during study, including respiratory and kidney diseases
Taking multivitamins while studying
Consumption of less than 80% of prescribed supplements
Consumption of other probiotics during the study
The need to take antibiotics
Getting pregnant
Requiring need for insulin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aspartate Aminotransferase. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: Standard enzymatic method.